- Current report filing (8-K)
16 März 2009 - 8:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported): March 16, 2009
Cougar
Biotechnology, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-33871
|
|
20-2903204
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
10990
Wilshire Blvd, Suite 1200
Los
Angeles, CA 90024
|
(Address of principal executive offices) (Zip Code)
|
(310) 943-8040
(Registrant’s telephone number, including area
code)
N/A
(Former name or former address, if changed
since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02. Other Events.
On March 16, 2009, Cougar Biotechnology, Inc. (the “Company”) issued a
press release announcing its financial results for the quarter and year
ended December 31, 2008. A copy of this press release is furnished
herewith as Exhibit 99.1. Pursuant to the rules and regulations of the
Securities and Exchange Commission, such exhibit and the information set
forth therein and in this Item 2.02 have been furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to
liability under that section nor shall they be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as shall be expressly set forth by specific
reference in such filing regardless of any general incorporation
language.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release dated March 16, 2009
|
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
COUGAR BIOTECHNOLOGY, INC.
|
|
|
|
|
|
|
Date:
|
March 16, 2009
|
By:
|
|
/s/ Charles R. Eyler
|
|
|
|
|
Charles R. Eyler
|
|
|
|
|
Treasurer and Sr. Vice President, Finance
|
INDEX TO EXHIBITS FILED WITH THIS REPORT
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release dated March 16, 2009.
|
3
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025